GLP-1/glucagon) and triple agonists (GLP-1/GIP/glucagon) are already approved or in advanced clinical development for diabetes and obesity, with translational studies now extending to neurodegeneration
administration of d-allulose (0.3 and 1 g kg 1 , 10 ml kg 1 ) or saline (10 ml kg 1 ), respectively
However, the short stability of NR in circulation and rate-limited utilization by the expression of NRKs restrict its clinical application
Ditano-Vzquez P, Torres-Pea JD, Galeano-Valle F, Prez-Caballero AI, Demelo-Rodrguez P, Lopez-Miranda J et al (2019) The Fluid Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive Oil
Comments: The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control